Table 1. Risk groups covered by the survey and influenza vaccine types recommended for use in these risk groups, by country, 2019/2020.

	Austria	Italy c	Spain-Valencia	UK-England
Children 6m-17y	QIVe or QIVc (≥9y-17y)a	Risk groups QIVe or QIVc (≥10y-17y)	-	-
Adults 18-64y	QIVe, QIVc	Risk groups QIVe, QIVc	-	Risk groups QIVe, QIVc
Adults ≥65y	aTIV, QIVeb, QIVcb	aTIV, QIVe, QIVc (aTIV is preferentially recommended in those aged ≥75y)	aTIV	aTIV, QIVc, TIV-HD
Any person with comorbidities or immunosuppression	aTIV, QIVe, QIVc	-	-	-

aTIV: adjuvanted trivalent influenza vaccine; m; months; QIVc: cell-based inactivated quadrivalent influenza vaccine; QIVe: egg-based inactivated quadrivalent influenza vaccine; TIV-HD: high-dose trivalent influenza vaccine; y: years.

^a Children: live attenuated influenza vaccine also recommended for children >2y, however not available in Austria in 2019/2020.

^b Adults ≥65y: in the event of intensive circulation of B strain only covered by quadrivalent vaccines.

^c TIV also recommended however this vaccine was not procured by Italian regions in 2019/2020.